A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
Trial report in Annals of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04401579 (A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults), which is not on this map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)
TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2020 to 2020Enrolled1,033ConditionsCOVID-19ArmsPlacebo, Remdesivir, Baricitinib
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 13 institutions in 2 countries.
Catharine I PaulesDivision of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania (C.I.P.).ORCID 0000-0002-9064-6678
Jing WangClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland (J.W., T.B.).
Kay M TomashekNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).ORCID 0000-0001-7741-7072
Tyler BonnettClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland (J.W., T.B.).ORCID 0000-0001-5545-6433
Kanal SinghNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).ORCID 0000-0002-6620-6920
Vincent C MarconiDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia (V.C.M.).ORCID 0000-0001-8409-4689
Richard T DaveyNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).ORCID 0000-0002-3992-5524
David C LyeNational Centre for Infectious Diseases, Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, and Lee Kong Chian School of Medicine, Singapore (D.C.L.).ORCID 0000-0003-0324-0205
Lori E DoddNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).
Otto O YangDivision of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California (O.O.Y.).ORCID 0000-0003-1970-8992
Constance A BensonDivision of Infectious Diseases & Global Public Health, University of California San Diego, San Diego, California (C.A.B.).ORCID 0000-0002-3781-1347
Gregory A DeyeNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).ORCID 0000-0001-5527-4541
Sarah B DoernbergDivision of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California (S.B.D.).ORCID 0000-0003-1727-6014
Noreen A HynesDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland (N.A.H.).ORCID 0000-0001-6898-0621
Robert GrossbergDivision of Infectious Diseases, Montefiore Medical Center, Bronx, New York (R.G.).ORCID 0000-0001-6322-8393
Cameron R WolfeDivision of Infectious Diseases, Duke University Medical Center, Durham, North Carolina (C.R.W.).ORCID 0000-0002-5365-5030
Seema U NayakNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).
William R ShortPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (W.R.S.).ORCID 0000-0003-4225-8336
Jocelyn VoellNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).
Gail E PotterNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).ORCID 0000-0001-6667-6992
Rekha R RapakaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland (R.R.R.).
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USDuke Medical Center · USEmory University · USJohns Hopkins University · USMontefiore Medical Center · USPenn State Milton S. Hershey Medical Center · USTan Tock Seng Hospital · SGUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of California System · USUniversity of Maryland, Baltimore · USUniversity of Pennsylvania · US
Funding
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
VTEU SupplementUM1AI148689 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Karen L. Kotloff · 2020 to 2026
$52.7M
Vanderbilt Vaccine and Treatment Evaluation Unit - KidCOVEUM1AI148452 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Clarence Buddy Creech · 2020 to 2026
$51.3M
Influenza and Emerging Infectious DiseasesZIAAI000984 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DAVEY, RICHARD · 2009 to 2025
$44.1M
Vaccine and Treatment Evaluation Units - DMID 21-0012UM1AI148576 · NIAID · EMORY UNIVERSITY · PI Nadine Georges Rouphael, Carlos del Rio · 2020 to 2026
$41.7M
Vaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6M
Vaccine and Treatment Evaluation Units (VTEU)-DMID 21-0004UM1AI148575 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HANA M EL SAHLY · 2020 to 2026
$29.4M
University of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012UM1AI148573 · NIAID · UNIVERSITY OF WASHINGTON · PI Raymond Scott McClelland, Anna Wald · 2020 to 2026
$26.6M
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric StudyUM1AI148450 · NIAID · UNIVERSITY OF ROCHESTER · PI Angela Ramona Branche, Ann R Falsey · 2020 to 2026
$20.6M
Human Cellular Immune Programming Against Invasive SalmonellaK08AI143923 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RAPAKA, REKHA R · 2019 to 2023
backgroundThe ACTT risk profile, which was developed from ACTT-1 (Adaptive COVID-19 Treatment Trial-1), demonstrated that hospitalized patients with COVID-19 in the high-risk quartile (characterized by low absolute lymphocyte count [ALC], high absolute neutrophil count [ANC], and low platelet count at baseline) benefited most from treatment with the antiviral remdesivir. It is unknown which patient characteristics are associated with benefit from treatment with the immunomodulator baricitinib.
objectiveTo apply the ACTT risk profile to the ACTT-2 cohort to investigate potential baricitinib-related treatment effects by risk quartile.
designPost hoc analysis of ACTT-2, a randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT04401579).
settingSixty-seven trial sites in 8 countries.
participantsAdults hospitalized with COVID-19 (
interventionBaricitinib+remdesivir versus placebo+remdesivir. MEASUREMENTS: Mortality, progression to invasive mechanical ventilation (IMV) or death, and recovery, all within 28 days; ALC, ANC, and platelet count trajectories.
resultsIn the high-risk quartile, baricitinib+remdesivir was associated with reduced risk for death (hazard ratio [HR], 0.38 [95% CI, 0.16 to 0.86]; LIMITATION: Secondary analysis of data collected before circulation of current SARS-CoV-2 variants.
conclusionThe ACTT risk profile identifies a subgroup of hospitalized patients who benefit most from baricitinib treatment and captures a patient phenotype of treatment response to an immunomodulator and an antiviral. Changes in ALC and ANC trajectory suggest a mechanism whereby an immunomodulator limits severe COVID-19. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.
Indexed as
AzetidinesCOVID-19PurinesPyrazolesSulfonamidesAdultAntiviral AgentsCOVID-19 Drug TreatmentDouble-Blind MethodHumansImmunologic FactorsSARS-CoV-2Treatment OutcomeAntiviral AgentsAzetidinesbaricitinibImmunologic FactorsPurinesPyrazolesSulfonamides
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. · full record | OpenQuestion